Floatz logo

Apl-501

Mismatch Repair Deficiency

Apollomics (Australia) Pty. Ltd.Phase 1Dormant
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
81/ 100

Competitive context

20 Active assets in the Mismatch Repair Deficiency cohort.

Asset / SponsorPhaseRating
Nivolumab
7 Hills Pharma, LLC
Phase 2B
Pembrolizumab
Jennifer Leddon
Phase 2B
Cyclophosphamide
Jennifer Leddon
Phase 2B
Danvatirsen
M.D. Anderson Cancer Center
Phase 2CCC
Fludarabine
Udai Kammula
Phase 2CCC

View all 25 →

Same molecule, other indications

Apl-501 is also rated in:

Microsatellite InstabilityDormant
CC
Indicative ·
47 / 100
View asset →
cancer of unknown primary siteDormant
CC
Indicative ·
47 / 100
View asset →
hepatocellular carcinomaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →